Consensus EPS · Q2 2026
$1.84
Consensus revenue · Q2 2026
$100.1B
Analysts
15
Expected report
Aug 5, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 15 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $97.4B | $100.1B | $105B |
| EPS | $1.48 | $1.84 | $1.94 |
| EBITDA | $4.1B | $4.2B | $4.3B |
| EBIT | $2.8B | $2.9B | $3B |
| Net income | $2.2B | $2.3B | $2.4B |
- Revenue$100.1B
- EPS$1.84
- EBITDA$4.2B
- EBIT$2.9B
- Net income$2.3B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $100.4B | $95B | +5.7% | $2.57 | $2.18 | +17.7% |
| Q4 2025 | $105.7B | $103.7B | +1.9% | $1.09 | $1.00 | +8.7% |
- Q1 2026+5.7%+17.7%
- Q4 2025+1.9%+8.7%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for CVS Health (CVS) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 5 analysts.
- Low
- $90.00
- Consensus
- $106.57
- Median
- $108.00
- High
- $123.00
- Current
- $108.08
- Upside
- -1.4%
Upside calculated vs most recent trading price of $108.08.
Analyst ratings
Consensus: Buy — based on 41 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 14, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 13, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 9, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Jul 7, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Jun 23, 2026 | B of A Securities | maintain | Buy | Buy |
| Jun 8, 2026 | Mizuho | maintain | Outperform | Outperform |
| Jun 4, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jun 1, 2026 | Truist Securities | maintain | Buy | Buy |
| May 26, 2026 | Barclays | maintain | Overweight | Overweight |
| May 20, 2026 | Mizuho | maintain | Outperform | Outperform |
- Jul 14, 2026Truist SecuritiesBuy
- Jul 13, 2026Wells FargoOverweight
- Jul 9, 2026RBC CapitalOutperform
- Jul 7, 2026Cantor FitzgeraldOverweight
- Jun 23, 2026B of A SecuritiesBuy
- Jun 8, 2026MizuhoOutperform
- Jun 4, 2026Morgan StanleyOverweight
- Jun 1, 2026Truist SecuritiesBuy
- May 26, 2026BarclaysOverweight
- May 20, 2026MizuhoOutperform
Frequently asked questions
CVS Health (CVS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks
- Dividend Profile2.46% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History4 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.